CD19-B Cell Depletion in PAIS-ME/CFS Patients

NCT07724834 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Post-acute Infectious Syndrome (PAIS)
Post-COVID 19 Condition (PCC or Long COVID)
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

Interventions

DRUG: Inebilizumab
DRUG: Placebo

Sponsor

Charite University, Berlin, Germany